{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:01:34Z","timestamp":1788012094122,"version":"build-2784847793"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","award":["2019-2022"],"award-info":[{"award-number":["2019-2022"]}],"id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010230","name":"Queensland Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jval.2024.06.019","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:27:12Z","timestamp":1720232832000},"page":"1515-1527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers"],"prefix":"10.1016","volume":"27","author":[{"given":"Srinivas","family":"Teppala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2024.06.019_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jval.2024.06.019_bib5","doi-asserted-by":"crossref","first-page":"e2336604","DOI":"10.1001\/jamanetworkopen.2023.36604","article-title":"Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy","volume":"6","author":"Corsini","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.jval.2024.06.019_bib7","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","article-title":"Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis","volume":"103","author":"Edwards","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/annonc\/mdw048","article-title":"PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations","volume":"27","author":"Helleday","year":"2016","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jval.2024.06.019_bib11","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jval.2024.06.019_bib12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2024.06.019_bib13","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3389\/fphar.2020.610601","article-title":"Cost-effectiveness of genomic test-directed olaparib for metastatic castration-resistant prostate cancer","volume":"11","author":"Su","year":"2021","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.jval.2024.06.019_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/pgs-2021-0061","article-title":"Is Olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?","volume":"22","author":"Li","year":"2021","journal-title":"Pharmacogenomics"},{"issue":"15","key":"10.1016\/j.jval.2024.06.019_bib15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.21037\/atm-22-3637","article-title":"Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States","volume":"10","author":"Xu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib18","first-page":"19","article-title":"A\u00a0review of the cost-effectiveness of genetic testing for germline variants in familial cancer","volume":"26","author":"Teppala","year":"2023","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2024.06.019_bib19","doi-asserted-by":"crossref","unstructured":"Tuffaha H, Edmunds K, Fairbairn D, et\u00a0al. Guidelines for genetic testing in prostate cancer: a scoping review. May 18, 2023. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00676-0","DOI":"10.1038\/s41391-023-00676-0"},{"issue":"4","key":"10.1016\/j.jval.2024.06.019_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/cancers14041004","article-title":"Clinical management of prostate cancer in high-risk genetic mutation carriers","volume":"14","author":"Clark","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jval.2024.06.019_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2020","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.jval.2024.06.019_bib24","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.jval.2024.06.019_bib25","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1634\/theoncologist.2019-0495","article-title":"Prognostic value of germline DNA repair gene mutations in de novo metastatic and castration-sensitive prostate cancer","volume":"25","author":"Wei","year":"2020","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.jval.2024.06.019_bib26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2024.06.019_bib28","author":"Qu"},{"key":"10.1016\/j.jval.2024.06.019_bib29","author":"Hayes"},{"issue":"3","key":"10.1016\/j.jval.2024.06.019_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the Impact study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localized prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.jval.2024.06.019_bib35","first-page":"985","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"15","key":"10.1016\/j.jval.2024.06.019_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.jval.2024.06.019_bib37","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jval.2024.06.019_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ajco.12582","article-title":"Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia","volume":"13","author":"Cronin","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib43","first-page":"1122","article-title":"Long-term outcomes of active surveillance for prostate cancer: the Memorial Sloan Kettering Cancer Center experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib44","first-page":"1222","article-title":"The long-term risks of metastases in men on active surveillance for early stage prostate cancer","volume":"204","author":"Maggi","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib45","first-page":"1117","article-title":"Risk of metastasis in men with grade Group 2 prostate cancer managed with active surveillance at a tertiary Cancer Center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"20","key":"10.1016\/j.jval.2024.06.019_bib46","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.34916","article-title":"Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system","volume":"129","author":"Herr","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2024.06.019_bib47","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2009.22.2265","article-title":"Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix","volume":"28","author":"Zelefsky","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2024.06.019_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21681805.2022.2108140","article-title":"Biochemical recurrence after radical prostatectomy - a large, comprehensive, population-based study with long follow-up","volume":"56","author":"Ax\u00e9n","year":"2022","journal-title":"Scand J Urol"},{"issue":"23","key":"10.1016\/j.jval.2024.06.019_bib49","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jval.2024.06.019_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5694\/mja13.10848","article-title":"Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers","volume":"199","author":"Collins","year":"2013","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the Impact study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"issue":"8","key":"10.1016\/j.jval.2024.06.019_bib53","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s11136-014-0676-x","article-title":"A\u00a0comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA","volume":"23","author":"Clemens","year":"2014","journal-title":"Qual Life Res"},{"issue":"12","key":"10.1016\/j.jval.2024.06.019_bib54","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jval.2021.06.001","article-title":"Cost-effectiveness of magnetic resonance imaging in prostate cancer screening: a microsimulation study","volume":"24","author":"Hao","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2024.06.019_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A\u00a0cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.jval.2024.06.019_bib57","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(20)30449-6","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jval.2024.06.019_bib58","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jval.2015.08.012","article-title":"Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients","volume":"18","author":"Lloyd","year":"2015","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2024.06.019_bib59","first-page":"1202","article-title":"Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance","volume":"22","author":"Barqawi","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jval.2021.07.002","article-title":"Systematic review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis","volume":"25","author":"Keeney","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2024.06.019_bib63","doi-asserted-by":"crossref","first-page":"91.e7","DOI":"10.1016\/j.urolonc.2017.10.024","article-title":"Estimating the healthcare costs of treating prostate cancer in Australia: a Markov modelling analysis","volume":"36","author":"Gordon","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib65","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1200\/OP.20.00399","article-title":"Evaluation of a mainstream model of genetic testing for men with prostate cancer","volume":"17","author":"Scheinberg","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98737-8","article-title":"Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design","volume":"11","author":"Blomen","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18773\/austprescr.2017.014","article-title":"Economic evaluation of medicines","volume":"40","author":"Taylor","year":"2017","journal-title":"Aust Prescr"},{"issue":"2","key":"10.1016\/j.jval.2024.06.019_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jval.2020.09.016","article-title":"Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review","volume":"24","author":"Koldehoff","year":"2021","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"10398","key":"10.1016\/j.jval.2024.06.019_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib71","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","article-title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","volume":"50","author":"Wedge","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jval.2024.06.019_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer","volume":"4","author":"Pollard","year":"2017","journal-title":"Asian J Urol"},{"issue":"9","key":"10.1016\/j.jval.2024.06.019_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jval.2024.06.019_bib75","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10147-021-01956-2","article-title":"Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents","volume":"26","author":"Miyake","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jval.2024.06.019_bib77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2024.06.019_bib109","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/IGC.0b013e3181dbd13f","article-title":"Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years","volume":"20","author":"Gordon","year":"2010","journal-title":"Int J Gynecol Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152402758X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152402758X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:55:38Z","timestamp":1762030538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152402758X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S109830152402758X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.019","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}